Shares of Poseida Therapeutics, Inc. (PSTX) have been strong performers lately, with the stock up 196% over the past month. The stock hit a new 52-week high of $9.58 in the previous session. Poseida Therapeutics, Inc. has gained 182.7% since the start of the year compared to the -1.7% move for the Zacks Medical sector and the -8.8% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't misse ...

From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover i ...

Shares of Poseida Therapeutics, Inc. (PSTX) have gained 282.9% over the past four weeks to close the last trading session at $9.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14 indicates a potential upside of 49.3%.The mean estimate comprises three short-term price targets with a standard deviation of $5.29. While the lowest estimate of $10 indicates a 6.6% increase from ...

Have you been paying attention to shares of Poseida Therapeutics, Inc. (PSTX) ? Shares have been on the move with the stock up 282.9% over the past month. The stock hit a new 52-week high of $9.41 in the previous session. Poseida Therapeutics, Inc. has gained 179.2% since the start of the year compared to the 1.5% move for the Zacks Medical sector and the -6.3% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings ...

NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Poseida Therapeutics, Inc. (NASDAQ: PSTX), relating to the proposed merger with Roche Holdings, Inc. Under the terms of the agreement, Poseida Therapeutics will be acquired at a price of $9.0 ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

SAN DIEGO, Nov. 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences:Stifel 2024 Healthcare ConferenceDate: Monday, November 18, 2024Time: 10:20am ETPiper Sandler 36th Annual Healthcare ConferenceDate: Wednesday, December 4, 20 ...

Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 150%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.32, delivering a surprise of 25.58%.Over the last four quarters, t ...

Core Insights - Poseida Therapeutics has made significant advancements in its allogeneic CAR-T therapy pipeline, particularly through collaborations with Roche and Astellas, and has achieved cash flow positivity for the first nine months of 2024, generating $130 million in milestone and upfront payments [1][2][20]. Financial Performance - Revenues for Q3 2024 were $71.7 million, and $125.9 million for the first nine months, compared to $9.4 million and $39.7 million for the same periods in 2023, primarily due to milestone recognition and increased R&D reimbursements [16][25]. - Research and development expenses increased to $41.9 million for Q3 2024 and $130.4 million for the first nine months, up from $37.5 million and $114.7 million in 2023, driven by the expansion of allogeneic clinical programs [17][25]. - General and administrative expenses rose to $10.1 million for Q3 2024 and $32.1 million for the first nine months, compared to $8.1 million and $28.6 million in 2023, attributed to higher legal, professional fees, and personnel costs [18][25]. - The net income for Q3 2024 was $20.2 million, while the net loss for the first nine months was $35.4 million, compared to a net loss of $31.8 million and $98.1 million for the same periods in 2023 [19][25]. Pipeline Developments - The company presented positive interim Phase 1 results for P-BCMA-ALLO1, showing a 91% overall response rate in heavily pretreated multiple myeloma patients, with a differentiated safety profile [1][4]. - P-BCMA-ALLO1 has been granted RMAT designation by the FDA for treating relapsed/refractory multiple myeloma after three or more prior therapies [5]. - Poseida introduced P-BCMACD19-ALLO1 as a wholly-owned program targeting autoimmune diseases and hematological malignancies, currently in IND-enabling studies [1][7]. Collaborations and Strategic Initiatives - The collaboration with Roche has expanded to include three programs, with Roche having the option to nominate additional candidates in the future [3][4]. - Astellas has nominated a second high-potential program target under their collaboration, focusing on well-known solid tumor targets [6]. Upcoming Events - Poseida will host a Cell Therapy R&D Day on November 14, 2024, to discuss progress and opportunities in its allogeneic CAR-T therapies [15].

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific MeetingSAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the upcoming presentation of new preclinical data supporting the potentia ...